Business · 02/05/2012Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Victoza Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the review period for a patent extension application for Novo Nordisk's Victoza, a human insulin drug, as required by law.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →